Contact us Media About Ferring > Sustainability > Protecting women and families Protecting women and families Postpartum haemorrhage is the leading direct cause of maternal death worldwide. Ferring is collaborating with organisations to address this together, as we believe that no woman should die while giving birth. Protecting women and families Reducing maternal mortality Collaborating to find new ways to protect people and families References Protecting women and families At Ferring, we believe everyone going through childbirth should have access to quality care and treatment to help them build families. This is why we are working to reduce the devastating impact that postpartum haemorrhage has on women and families around the world. Reducing maternal mortality Every year, 14 million women suffer from PPH, or excessive bleeding after childbirth.¹ This causes 70,000 deaths a year, 90% of which are in low- and lower middle-income countries.² Most of these deaths are preventable with uterotonic medicines, which help the uterus to contract and stop the bleeding. Ferring scientists developed a uterotonic compound called carbetocin which has been approved since 1997. To find out more about the impact of PPH globally take a look at our infographic. Read more on what Ferring is doing to improve Safe Birth for women around the world. Collaborating to find new ways to protect people and families Ferring developed a heat-stable formulation of carbetocin to specifically address limitations in refrigeration and cold-chain transport of PPH medications in low- and lower-middle income countries. Heat-stable carbetocin was researched and developed as part of the CHAMPION (*Carbetocin Haemorrhage Prevention) trial programme, the largest ever randomized study in the prevention of PPH, in collaboration with WHO and Merck for Mothers. Results of the CHAMPION trial published in the New England Journal of Medicine were announced in 2018, see here. Ferring and key partners are working to bring access to heat-stable carbetocin in low- and lower-middle income countries, where the burden of maternal mortality is greatest. References World Health Organization. Priority diseases and reasons for inclusion. Postpartum haemorrhage. Available at: http://www.who.int/medicines/areas/priority_medicines/Ch6_16PPH.pdf Last accessed: June 2021. Say L, et al. Global causes of maternal death: a WHO systematic analysis. The Lancet Global Health. 2014; 2(6):e323-33. Available at: https://www.thelancet.com/pdfs/journals/langlo/PIIS2214-109X(14)70227-X.pdf Last accessed: June 2021. ©Joni Kabana Photography/Concept Foundation/Ferring Pharmaceuticals/MSD for Mothers Learn more about Ferring’s commitment to reducing maternal mortality LEARN MORE At Ferring, we are committed to building families worldwide and helping people live better lives. We are a leader in reproductive medicine and maternal health, gastroenterology and urology. Legal Legal disclaimer Privacy Cookies Contact us Global Locator Media enquiries Report a side effect Ferring Worldwide Select country and territory Select country and territory Albania Algeria Angola Argentina Armenia Australia Austria Azerbaijan Bahrain Belgium Bolivia Bosnia and Herzegovina Brazil Bulgaria Burkina Faso Cameroon Canada Chile China, M&S China, Manufacturing China, R&D Colombia Congo Costa Rica Croatia Cuba Czech Republic, Manufacturing Czech Republic, Marketing & Sales Denmark, IPC, Research & Development Denmark, Manufacturing Denmark, Marketing & Sales Dominican Republic Ecuador Egypt El Salvador Ethiopia Finland France Gabon Georgia Germany, Manufacturing Germany, Marketing & Sales Ghana Greece Guatemala Hong Kong Hungary India, IPC Research & Development India, Manufacturing India, Marketing & Sales Iran Iraq Ireland Israel, BTG, Manufacturing and Research & Development Israel, Marketing & Sales Italy Ivory Coast Japan Jordan Kazakhstan Kenya Korea Kosovo Kuwait Kyrgyzstan Lebanon Libya Macedonia Madagascar Malaysia Mali Mauritania Mauritius Mexico, Commercial Office Mexico, Manufacturing Middle East, Turkey & Africa Regional Office Moldovia Mongolia Montenegro Morocco Niger Nigeria Norway Oman Pakistan Panama Paraguay Peru Philippines Poland Portugal Qatar Romania Russia Saudi Arabia Senegal Serbia Singapore Slovakia Slovenia South Africa Spain Sudan Sweden Switzerland, Global Headquarters Switzerland, Marketing & Sales Switzerland, Marketing & Sales Switzerland, Research & Development Syria Taiwan Tajikistan Tanzania Thailand The Netherlands Togo Trinidad and Tobago & Carib.Islands Tunisia Turkey Turkmenistan Uganda UK Manufacturing, Research & Development UK Marketing & Sales Ukraine United Arab Emirates US, Ferring Research Institute (FRI) US, FIPCUS, Research & Development US, FPI, Marketing & Sales US, Manufacturing US, REBIOTIX INC. Manufacturing, Research & Development Uzbekistan Venezuela Vietnam, HANOI Marketing Vietnam, HCMC Marketing Yemen This global corporate website provides general information about the global Ferring Group. For information about Ferring or its products in a specific country, please select your country in the Global Locator. FERRING, the FERRING PHARMACEUTICALS logo and other Ferring product trade names are trademarks of Ferring B.V. save where indicated otherwise. ©2021 Ferring B.V. Ferring would like to use cookies to better understand your use of this website and improve your experience while navigating it. Please accept our use of cookies in accordance with our privacy policy. Accept Decline